208 related articles for article (PubMed ID: 33687063)
1. Multilevel Factors Associated With More Intensive Use of Radioactive Iodine for Low-Risk Thyroid Cancer.
Wallner LP; Banerjee M; Reyes-Gastelum D; Hamilton AS; Ward KC; Lubitz C; Hawley ST; Haymart MR
J Clin Endocrinol Metab; 2021 May; 106(6):e2402-e2412. PubMed ID: 33687063
[TBL] [Abstract][Full Text] [Related]
2. Patient-Perceived Lack of Choice in Receipt of Radioactive Iodine for Treatment of Differentiated Thyroid Cancer.
Wallner LP; Reyes-Gastelum D; Hamilton AS; Ward KC; Hawley ST; Haymart MR
J Clin Oncol; 2019 Aug; 37(24):2152-2161. PubMed ID: 31283406
[TBL] [Abstract][Full Text] [Related]
3. Factors that influence radioactive iodine use for thyroid cancer.
Papaleontiou M; Banerjee M; Yang D; Sisson JC; Koenig RJ; Haymart MR
Thyroid; 2013 Feb; 23(2):219-24. PubMed ID: 23134514
[TBL] [Abstract][Full Text] [Related]
4. Disparity in the use of adjuvant radioactive iodine ablation among high-risk papillary thyroid cancer patients.
Moten AS; Zhao H; Intenzo CM; Willis AI
Eur J Surg Oncol; 2019 Nov; 45(11):2090-2095. PubMed ID: 31253543
[TBL] [Abstract][Full Text] [Related]
5. Use of evidence-based guidelines reduces radioactive iodine treatment in patients with low-risk differentiated thyroid cancer.
Sacks W; Wong RM; Bresee C; Braunstein GD
Thyroid; 2015 Apr; 25(4):377-85. PubMed ID: 25578116
[TBL] [Abstract][Full Text] [Related]
6. Too Much of a Good Thing: Radioactive Iodine Ablation Use for Micropapillary Thyroid Carcinoma.
Chae AW; Martinez SR
Am Surg; 2018 May; 84(5):637-643. PubMed ID: 29966562
[TBL] [Abstract][Full Text] [Related]
7. The overuse of radioactive iodine in low-risk papillary thyroid cancer patients.
Moten AS; Zhao H; Willis AI
Surg Oncol; 2019 Jun; 29():184-189. PubMed ID: 31196486
[TBL] [Abstract][Full Text] [Related]
8. Risk of Hematologic Malignancies After Radioiodine Treatment of Well-Differentiated Thyroid Cancer.
Molenaar RJ; Sidana S; Radivoyevitch T; Advani AS; Gerds AT; Carraway HE; Angelini D; Kalaycio M; Nazha A; Adelstein DJ; Nasr C; Maciejewski JP; Majhail NS; Sekeres MA; Mukherjee S
J Clin Oncol; 2018 Jun; 36(18):1831-1839. PubMed ID: 29252123
[TBL] [Abstract][Full Text] [Related]
9. Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy.
Iyer NG; Morris LG; Tuttle RM; Shaha AR; Ganly I
Cancer; 2011 Oct; 117(19):4439-46. PubMed ID: 21432843
[TBL] [Abstract][Full Text] [Related]
10. Knowledge of pathologically versus clinically negative lymph nodes is associated with reduced use of radioactive iodine post-thyroidectomy for low-risk papillary thyroid cancer.
Ruel E; Thomas S; Dinan MA; Perkins JM; Roman SA; Sosa JA
Endocrine; 2016 Jun; 52(3):579-86. PubMed ID: 26708045
[TBL] [Abstract][Full Text] [Related]
11. Radioactive iodine in differentiated thyroid cancer: a national database perspective.
Orosco RK; Hussain T; Noel JE; Chang DC; Dosiou C; Mittra E; Divi V; Orloff LA
Endocr Relat Cancer; 2019 Oct; 26(10):795-802. PubMed ID: 31443087
[TBL] [Abstract][Full Text] [Related]
12. Radioiodine-Induced Salivary Gland Damage Detected by Ultrasonography in Patients Treated for Papillary Thyroid Cancer: Radioactive Iodine Activity and Risk.
Horvath E; Skoknic V; Majlis S; Tala H; Silva C; Castillo E; Whittle C; Niedmann JP; González P
Thyroid; 2020 Nov; 30(11):1646-1655. PubMed ID: 32370663
[No Abstract] [Full Text] [Related]
13. Thyrotropin Suppression for Papillary Thyroid Cancer: A Physician Survey Study.
Papaleontiou M; Chen DW; Banerjee M; Reyes-Gastelum D; Hamilton AS; Ward KC; Haymart MR
Thyroid; 2021 Sep; 31(9):1383-1390. PubMed ID: 33779292
[No Abstract] [Full Text] [Related]
14. Disease severity and radioactive iodine use for thyroid cancer.
Haymart MR; Muenz DG; Stewart AK; Griggs JJ; Banerjee M
J Clin Endocrinol Metab; 2013 Feb; 98(2):678-86. PubMed ID: 23322816
[TBL] [Abstract][Full Text] [Related]
15. The Effect of Radioactive Iodine Therapy on Ovarian Function and Fertility in Female Thyroid Cancer Patients: A Systematic Review and Meta-Analysis.
Piek MW; Postma EL; van Leeuwaarde R; de Boer JP; Bos AME; Lok C; Stokkel M; Filipe MD; van der Ploeg IMC
Thyroid; 2021 Apr; 31(4):658-668. PubMed ID: 33012254
[No Abstract] [Full Text] [Related]
16. Adjuvant radioactive iodine use among differentiated thyroid cancer patients in the military health system.
Gill AA; Enewold L; Zahm SH; Shriver CD; Zheng L; McGlynn KA; Zhu K
Mil Med; 2014 Sep; 179(9):1043-50. PubMed ID: 25181724
[TBL] [Abstract][Full Text] [Related]
17. Timing of Radioactive Iodine Administration Does Not Influence Outcomes in Patients with Differentiated Thyroid Carcinoma.
Scheffel RS; Zanella AB; Dora JM; Maia AL
Thyroid; 2016 Nov; 26(11):1623-1629. PubMed ID: 27549175
[TBL] [Abstract][Full Text] [Related]
18. Use of Radioactive Iodine for Thyroid Cancer and Risk of Second Primary Malignancy: A Nationwide Population-Based Study.
Teng CJ; Hu YW; Chen SC; Yeh CM; Chiang HL; Chen TJ; Liu CJ
J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26538627
[TBL] [Abstract][Full Text] [Related]
19. Increased risk of second primary malignancy in pediatric and young adult patients treated with radioactive iodine for differentiated thyroid cancer.
Marti JL; Jain KS; Morris LG
Thyroid; 2015 Jun; 25(6):681-7. PubMed ID: 25851829
[TBL] [Abstract][Full Text] [Related]
20. Comparison between the different doses of radioactive iodine ablation prescribed in patients with intermediate-to-high-risk differentiated thyroid cancer.
Iizuka Y; Katagiri T; Ogura K; Mizowaki T
Ann Nucl Med; 2019 Jul; 33(7):495-501. PubMed ID: 30955202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]